Boston Children's Hospital

Researchers at University of Rochester and Harvard Medical School developed CBD-IN, a nano-micelle formulation that successfully crosses the blood-brain barrier and provides neuropathic pain relief within 30 minutes in mice.

Ovid Therapeutics announced positive Phase 1 results for OV329, a next-generation GABA-aminotransferase inhibitor, showing 53% inhibition of GABA-AT at 5 mg dose with statistical significance (p=0.0001).

Apertura Gene Therapy has licensed its novel TfR1 CapX capsid technology to Galibra Neuroscience and Emugen Therapeutics for central nervous system gene therapy programs.

A comprehensive analysis of insulin out-of-pocket costs and usage patterns from 2008-2021 reveals persistent disparities in insulin access between higher-income and lower-income patients with diabetes.

Dana-Farber Cancer Institute, Boston Children's Hospital, and Broad Clinical Labs have formed BrightSeq, a collaborative initiative to develop clinical molecular testing assays specifically for pediatric cancers.

The first commercial gene therapy treatments ever delivered directly to the brain in the United States have been successfully performed using ClearPoint Neuro's SmartFlow Neuro Cannula to administer KEBILIDI for AADC deficiency.

NS Pharma's parent company Nippon Shinyaku has finalized a strategic partnership with Boston Children's Hospital to develop innovative therapies for rare diseases.

Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).

Children with uncontrolled moderate to severe asthma experienced significantly fewer exacerbations when treated with dupilumab compared to placebo, regardless of how long they had been living with the disease.

The FDA has cleared BlackfinBio's IND application to begin a Phase 1/2 clinical trial of BFB-101, a gene therapy designed to treat Hereditary Spastic Paraplegia Type 47 (SPG47), a rare neurological disorder with no existing treatments.